NRX Pharmaceuticals (NRXP) Cash & Equivalents (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Cash & Equivalents data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 21.82% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 21.82% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, up 440.33% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $6.7 million, down from $7.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NRXP reached as high as $40.2 million in Q1 2022 and fell as low as $1.3 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $10.8 million across 5 years, with a median of $7.2 million in 2025.
• Across the five-year window, Cash & Equivalents slumped 92.01% in 2024 and soared 440.33% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $20.1 million in 2022, then slumped by 77.09% to $4.6 million in 2023, then tumbled by 68.6% to $1.4 million in 2024, then surged by 440.33% to $7.8 million in 2025, then dropped by 14.07% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $6.7 million in Q1 2026, $7.8 million in Q4 2025, and $7.2 million in Q3 2025.